BlackRock Inc. reduced its holdings in FibroGen Inc (NASDAQ:FGEN) by 2.2% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 6,172,887 shares of the biopharmaceutical company’s stock after selling 136,356 shares during the period. BlackRock Inc. owned approximately 0.07% of FibroGen worth $335,497,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. Lindbrook Capital LLC increased its position in FibroGen by 150.0% in the 1st quarter. Lindbrook Capital LLC now owns 500 shares of the biopharmaceutical company’s stock worth $27,000 after buying an additional 300 shares during the period. FTB Advisors Inc. bought a new position in FibroGen in the 1st quarter worth approximately $27,000. Manchester Capital Management LLC bought a new position in FibroGen in the 1st quarter worth approximately $39,000. Cornerstone Advisors Inc. increased its position in FibroGen by 672.8% in the 1st quarter. Cornerstone Advisors Inc. now owns 796 shares of the biopharmaceutical company’s stock worth $43,000 after buying an additional 693 shares during the period. Finally, Quadrant Capital Group LLC bought a new position in FibroGen in the 1st quarter worth approximately $45,000. 66.27% of the stock is currently owned by institutional investors.

FibroGen stock opened at $40.20 on Thursday. The company has a current ratio of 6.16, a quick ratio of 6.16 and a debt-to-equity ratio of 0.09. The firm has a market capitalization of $3.40 billion, a price-to-earnings ratio of -39.03 and a beta of 1.75. FibroGen Inc has a 52 week low of $33.51 and a 52 week high of $68.55.

FibroGen (NASDAQ:FGEN) last posted its quarterly earnings data on Thursday, May 9th. The biopharmaceutical company reported ($0.53) EPS for the quarter, topping analysts’ consensus estimates of ($0.68) by $0.15. The company had revenue of $23.90 million for the quarter, compared to analyst estimates of $20.44 million. FibroGen had a negative return on equity of 17.71% and a negative net margin of 44.14%. The business’s revenue was down 25.1% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.50) earnings per share. Research analysts anticipate that FibroGen Inc will post -0.87 earnings per share for the current year.

In other news, CEO Thomas B. Neff sold 39,636 shares of the company’s stock in a transaction on Thursday, March 21st. The stock was sold at an average price of $55.52, for a total transaction of $2,200,590.72. Following the transaction, the chief executive officer now owns 2,596,440 shares of the company’s stock, valued at $144,154,348.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Pat Cotroneo sold 7,665 shares of the company’s stock in a transaction on Tuesday, March 19th. The shares were sold at an average price of $55.41, for a total value of $424,717.65. Following the transaction, the senior vice president now directly owns 239,504 shares in the company, valued at approximately $13,270,916.64. The disclosure for this sale can be found here. In the last three months, insiders sold 251,495 shares of company stock worth $11,234,313. Insiders own 7.83% of the company’s stock.

A number of analysts have recently issued reports on the company. ValuEngine cut FibroGen from a “buy” rating to a “hold” rating in a research report on Friday, May 10th. Zacks Investment Research upgraded FibroGen from a “hold” rating to a “buy” rating and set a $62.00 price target on the stock in a research report on Friday, March 8th. BidaskClub cut FibroGen from a “hold” rating to a “sell” rating in a research report on Tuesday, April 16th. Piper Jaffray Companies assumed coverage on FibroGen in a research report on Friday, April 12th. They issued a “neutral” rating and a $65.00 price target on the stock. Finally, TheStreet upgraded FibroGen from a “d+” rating to a “c-” rating in a research report on Friday, March 29th. Five research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. FibroGen has an average rating of “Buy” and a consensus price target of $61.57.

COPYRIGHT VIOLATION WARNING: This story was originally posted by Daily Political and is owned by of Daily Political. If you are accessing this story on another site, it was stolen and reposted in violation of international copyright & trademark legislation. The correct version of this story can be viewed at https://www.dailypolitical.com/2019/06/13/fibrogen-inc-nasdaqfgen-holdings-reduced-by-blackrock-inc.html.

FibroGen Profile

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases (HIF-PHs) that is in Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States and Europe; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes.

Further Reading: What is Forex?

Want to see what other hedge funds are holding FGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for FibroGen Inc (NASDAQ:FGEN).

Institutional Ownership by Quarter for FibroGen (NASDAQ:FGEN)

Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.